ZYZinan Yi

Zinan Yi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zinan Yi has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cost-effectiveness analysis of pneumococcal conjugate vaccines, PCV21 vs PCV20, in adults aged ≥60 years in Germany

    by Muloongo Simuzingili, Peter P. Mueller, Lisa M. Oexle, Marion de Lepper, Zinan Yi, Kwame Owusu-Edusei

    1. S. pneumoniae is a gram-positive bacterium with over 100 distinct serotypes, defined by differences in polysaccharide capsule proteins [1].Approximately one-third of pneumococcal serotypes cause...

  • Open Access

    The Health and Economic Impact of the Adult-specific 21-valent (aPCV21) Pneumococcal Conjugate Vaccine vs PCV20 on Invasive Pneumococcal Disease Among Adults Aged 65 years in the United Kingdom: A Modeling Study

    by Peter P. Mueller, Muloongo Simuzingili, Ian R. Matthews, Zinan Yi, Kwame Owusu-Edusei

    Introduction: This study compared the health and economic impact of the 21-valent pneumococcal conjugate vaccine (aPCV21) vs the 20-valent pneumococcal conjugate vaccine (PCV20) on invasive pneumococcal disease (IPD) and post-meningitis sequelae (PMS) among adults aged 65 years and older in the United Kingdom (UK). Methods: A published Markov model was used to simulate a single-cohort of vaccine-naïve adults who became eligible for age-based vaccination at age 65 years, with uptake occurring over time. The cohort was followed until a maximum age of 100 years. Model inputs were derived from publicly available national health data and published reports. Outcomes were discounted at 3.5% annually, and costs were adjusted to the 2024 Great Britain Pound (£). Additional analyses explored the impact of changing the age-based recommendation from 65 years to 75 years. Scenarios involving instantaneous vaccine uptake rates were included as part of the sensitivity analyses. A deterministic sensitivity analysis was performed on the incremental direct medical costs between vaccinating with aPCV21 vs PCV20 under the age-based recommendation of 65 years. Results: Using an age-based recommendation of 65 years, aPCV21 led to fewer cases, deaths, and costs than PCV20. Compared with PCV20, aPCV21 averted an additional 138 IPD cases, 1 PMS case, and 22 IPD deaths, saving £1.2 million in direct medical costs. Raising the age-based recommendation from 65 to 75 years and using aPCV21 (or PCV20, respectively), resulted in 120 (92) additional IPD cases, 2 (1) additional PMS case(s), 19 (14) additional IPD death(s), and an extra £1.1 (£0.8) million in direct medical costs. The deterministic sensitivity analysis showed that aPCV21 reduced direct medical costs across all parameter ranges. Conclusions: Compared with PCV20, aPCV21 prevented more IPD cases, IPD deaths, and direct medical costs among older adults in the UK. Changing the age-based recommendation from age 65 to 75 resulted in worse health and economic outcomes.

  • Open Access

    Cost-effectiveness analysis of pneumococcal vaccination of at-risk and high-risk adults aged 18–64 years in Switzerland using PCV21

    by Muloongo Simuzingili, Zinan Yi, Andrea Favre-Bulle, Thomas Mutschler, Eleana Tsoumani, Kwame Owusu-Edusei

    Pneumococcal disease (PD) collectively describes Streptococcus pneumoniae infections at various anatomical sites1,2. Infections of usually sterile sites are classified as invasive pneumococcal dise...

  • Open Access

    Economic Evaluation of PCV21 Use in Populations with Increasing Serotype 4 Invasive Pneumococcal Disease in the US: An Attributable Fraction Threshold Analysis

    by Zinan Yi, Kwame Owusu-Edusei, Elmira Flem, Kristen Feemster, Elamin H. Elbasha

    The 21-valent pneumococcal conjugate vaccine (PCV21) covers 83-88% of IPD in US adults but does not include serotype 4 (ST4), which is covered by previously recommended vaccines (PPSV23, PCV15, PCV20). Recent increases in IPD cases due to ST4 have been observed, particularly among adults under 65, including Native American/Alaskan Native and those with social risk factors. As a result, the Advisory Committee on Immunization Practices (ACIP) recommends ST4-containing vaccines (PPSV23, PCV15, and PCV20) for populations with ≥ 30% ST4 IPD cases. In this study, we aimed to analyze ST4 attributable fraction (AF) thresholds for health and economic outcomes of PCV21 versus PCV20 vaccination in US adults aged 19-49 and 50-64 years with underlying medical conditions. We used a validated Markov model to estimate incremental cost-effectiveness ratios (ICERs) for PCV21 versus PCV20 and identified ST4 AF thresholds in which the ICER shifted from 'cost-saving' to 'not cost-effective'. The analysis involved a hypothetical 1 million at-risk adults aged 19-49 and 50-64 years. PCV21 remained cost-saving compared to PCV20 when ST4 accounted for ≤ 27% (age 19-49) or ≤ 36% (age 50-64) of IPD. When ST4 increases were applied to both IPD and NBPP, these thresholds decreased to ≤ 21% and ≤ 28%, respectively. For populations experiencing moderate increases in the proportion of ST4 (i.e., < 30%), PCV21 may offer health and economic benefits over PCV20 for US adults aged 19-64 years with underlying medical conditions. However, in populations with ≥ 30% ST4, ST4-containing vaccines should be used as per ACIP guidance.


  • Open Access

    Delta price cost-effectiveness analysis of PCV21 vs PCV20 use in adults aged ≥65 years in Switzerland

    by Muloongo Simuzingili, Andrea Favre-Bulle, Thomas Mutschler, Zinan Yi, Eleana Tsoumani, Kwame Owusu-Edusei

    This study evaluated the health and economic impacts of the 21-valent pneumococcal conjugate vaccine (PCV21) compared to the 20-valent pneumococcal conjugate vaccine (PCV20) in Swiss adults aged 65 years and older using the delta-price approach. A published state-transition Markov model was used to track health and economic outcomes of invasive pneumococcal disease (IPD), inpatient non-bacteremic pneumococcal pneumonia (NBPP), and post-meningitis sequelae (PMS). Estimated quality-adjusted life years (QALYs)and cost outcomes were discounted at 3%. All costs were presented in 2024 Swiss Franc (CHF). Price premiums were estimated as the difference between the prices of PCV21 and PCV20, and the maximum premiums at which PCV21 remains cost-saving and cost-effective (at a willingness-to-pay threshold of CHF 40,000) were reported. A scenario analysis was conducted to include a pneumococcal polysaccharide vaccine 23-valent (PPSV23) and 13-valent pneumococcal conjugate vaccine (PCV13) vaccine-experienced population. Sensitivity analysis identified the input categories that were most influential on the price premiums. Overall, PCV21 averted more cases of IPD, NBPP, PMS and associated deaths, and saved more direct costs than PCV20. Compared to PCV20, PCV21 was cost-saving until a price premium of CHF 25.10 and cost-effective up to a price premium of CHF 88.01. In the scenario analysis, PCV21 was cost-saving up to a price premium of CHF 25.38, and cost-effective up to a price premium of CHF 88.68. Vaccine effectiveness and disease costs were the most influential inputs on the price premiums. PCV21 provides greater health and economic benefits than PCV20 and is cost-effective over a range of price premiums.


  • Open Access

    Estimating the Health and Economic Burden of Pneumococcal Diseases Attributable to PCV21 Versus PCV20 or PPSV23 Serotypes Among Adults in Norway

    by Zinan Yi, Athar Ali Tajik, Søren Toksvig Klitkou, Eleana Tsoumani, Kwame Owusu-Edusei

    Introduction Routine childhood immunization programs using pneumococcal conjugate vaccines (PCVs) significantly reduce the burden of pneumococcal disease (PD). PCV21, a 21-valent PCV, was recently approved and recommended by the European Commission for use in Norway. The objective of this study was to quantify the health and economic burden of invasive PD (IPD) and non-bacteremic pneumococcal pneumonia (NBPP) attributable to PCV21, PCV20, and PPSV23 serotypes among adults in Norway. Methods A published Markov model was adapted to estimate lifetime IPD/NBPP cases, deaths, and direct medical costs (in 2023 Norwegian kroner [NOK]) associated with PCV21, PCV20, and PPSV23 serotypes in Norway. Results were disaggregated by age and risk groups. A one-way sensitivity analysis examined changes in disease costs (± 20%). Results The projected number of PD cases and deaths attributable to PCV21 serotypes was substantially higher than those attributable to PCV20 and PPSV23 serotypes. PD cases and deaths attributable to PCV21 serotypes vs. PCV20 and PPSV23 were ~ 41% and ~ 26% higher, respectively, in adults aged 65+ years, ~ 39% and ~ 25% higher in those aged 50–64 years, and ~ 37% and ~ 22% higher in those aged 18–64 years with risk factors. Within each age group, cases and total lifetime costs increased progressively as risk categorization increased. Estimated lifetime direct treatment costs for PD attributable to PCV21 serotypes were higher than those associated with PCV20 or PPSV23, at 3.9 billion NOK, 3.5 billion NOK, and 4.4 billion NOK in adults aged 65+, 50–64, and 18–64 years with risk factors, respectively. Conclusions Compared with PCV20 and PPSV23, PCV21 serotypes are associated with a higher health and economic burden in Norway. The inclusion of PCV21 into national vaccine recommendations in Norway can further alleviate the burden associated with PD in adults.


  • Open Access

    Economic evaluation of PCV21 in PCV-naïve adults aged 50–64 years in the United States

    by Zinan Yi, Kwame Owusu-Edusei, Elamin H. Elbasha


  • Open Access

    Economic evaluation of PCV21 in vaccine-naïve adults aged 19–64 years with underlying medical conditions in the United States

    by Zinan Yi, Elamin H. Elbasha, Kwame Owusu-Edusei

    This study aimed to estimate the incremental health and economic outcomes associated with the use of PCV21 (Capvaxive™) in vaccine-naive adults aged 19-64 years with underlying medical conditions in the United States. A static multi-cohort state-transition Markov model was utilized, drawing on data from published literature and publicly available databases and reports, comparing PCV21 (intervention) versus PCV20 or PCV15 + PPSV23 (comparator) from a societal perspective with a lifetime horizon. The target population consisted of vaccine-naive adults aged 19-64 years classified as at-risk (AR) or high-risk (HR). Key outcome measures included undiscounted clinical cases: invasive pneumococcal disease (IPD), inpatient and outpatient non-bacteremic pneumococcal pneumonia (NBPP), post-meningitis sequelae (PMS), deaths from IPD and inpatient NBPP, as well as discounted quality-adjusted life years (QALYs), and total costs (in 2023 USD), with the incremental cost-effectiveness ratios (ICERs) reported as $/QALY gained. Costs and QALYs were discounted at 3% per year. Deterministic and probabilistic sensitivity analyses were conducted. The analysis indicated that the V116 strategy prevented a substantial number of cases and deaths compared to the PCV20 or PCV15 + PPSV23 strategies among vaccine-naive AR/HR adults aged 19-49 and 50-64 years. For instance, the use of PCV21 was projected to reduce IPD cases by 1,450 and 4,232, respectively, in the two age groups when compared with PCV20. The estimated ICERs for both age groups were found to be cost-saving when compared to both PCV20 and PCV15 + PPSV23. Deterministic and probabilistic sensitivity analyses confirmed the robustness of these findings, with over 95% of simulations yielding cost-saving results and all estimated ICERs remaining below $10,000/QALY gained. The findings suggest that the use of PCV21 (Capvaxive™) in adults aged 19-64 years with underlying medical conditions in the US can prevent a significant number of pneumococcal disease cases and deaths while demonstrating favorable economic outcomes across various scenarios.